[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100644487":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":10,"centralContacts":20,"locations":10,"responsibleParty":26,"collaborators":10,"id":29,"slug":30,"hasResults":31,"nctId":32,"briefTitle":33,"officialTitle":34,"acronym":10,"eligibilityCriteria":35,"healthyVolunteers":31,"sex":36,"minAge":37,"maxAge":10,"enrollmentInfo":38,"targetDuration":41,"studyType":42,"phases":10,"briefSummary":43,"conditions":44,"keywords":48,"overallStatus":53,"whyStopped":10,"lastUpdateSubmitDate":54,"lastUpdatePostDateStruct":55,"startDateStruct":58,"completionDateStruct":60,"leadSponsor":62,"locationsCount":10},{"fullName":5,"class":6},"Asan Medical Center","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Advanced Epithelial Ovarian Cancer Cohort",null,"Patients with FIGO stage III-IV high-grade serous, endometrioid, clear cell, or mixed type ovarian cancer who have completed primary or interval debulking surgery and platinum-based chemotherapy, and show a complete response. This cohort will undergo non-invasive blood-based minimal residual disease (MRD) monitoring using an NGS-based ctDNA assay (AlphaLiquid®100) to evaluate its utility in predicting recurrence.",[13],"Diagnostic Test: Blood-based ctDNA minimal residual disease (MRD) test",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":10},"DIAGNOSTIC_TEST","Blood-based ctDNA minimal residual disease (MRD) test","A non-invasive diagnostic blood test designed to monitor minimal residual disease (MRD). The procedure involves extracting cell-free DNA (cfDNA) from peripheral blood plasma and performing Next-Generation Sequencing (NGS) using a validated multigene assay (AlphaLiquid 100). This test detects and quantifies tumor-specific genetic mutations (Variant Allele Frequency \\[VAF\\] ≥ 0.1%) to evaluate molecular-level recurrence after the completion of standard first-line therapy.",[9],[21],{"name":22,"role":23,"phone":24,"phoneExt":10,"email":25},"Jeong-Yeol Park, MD, PhD","CONTACT","+82-2-3010-3646","catgut1-0@hanmail.net",{"type":27,"investigatorFullName":22,"investigatorTitle":28,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"PRINCIPAL_INVESTIGATOR","Professor","100644487","blood-based-minimal-residual-disease-in-advanced-epithelial-ovarian-cancer-after-1st-line-therapy-100644487",false,"NCT07670962","Blood-Based Minimal Residual Disease in Advanced Epithelial Ovarian Cancer After 1st Line Therapy","The Role of Blood-Based Minimal Residual Disease in Patients With Advanced Epithelial Ovarian Cancer After 1st Line Therapy","Inclusion Criteria:\n\nWomen aged 19 years or older. Pathologically confirmed high-grade serous, endometrioid, clear cell, or mixed type ovarian cancer.\n\nFIGO stage III or IV. Patients who have completed primary debulking surgery (PDS) or interval debulking surgery (IDS) and platinum-based chemotherapy (subsequent maintenance therapy, such as bevacizumab or PARP inhibitors, is allowed).\n\nPatients showing radiological or clinical Complete Response (CR) after the completion of platinum-based chemotherapy.\n\nWritten informed consent for the study.\n\nExclusion Criteria:\n\nRadiological progressive disease during or immediately after treatment. Expected survival of 3 months or less. Immunodeficiency or pathological bleeding tendencies. Unable to undergo blood tests or unwilling to undergo repeated blood sampling. Concurrent other solid tumors or history of malignant tumors within the last 5 years.\n\nRefusal to consent to participate in this study.","FEMALE","19 Years",{"count":39,"type":40},300,"ESTIMATED","3 Years","OBSERVATIONAL","The purpose of this observational study is to learn if a specialized blood test can help predict whether advanced ovarian cancer will return after a patient's initial treatments are finished.\n\nResearchers are inviting women who have been diagnosed with stage III or IV epithelial ovarian cancer and have recently completed their first-line treatments, which include surgery and platinum-based chemotherapy.\n\nThe study focuses on \"circulating tumor DNA\" (ctDNA), which are tiny fragments of genetic material that cancer cells release into the bloodstream as they break down. Finding these DNA fragments in the blood when a patient appears to be cancer-free on standard tests is known as assessing for minimal residual disease (MRD).\n\nBecause this is an observational study, participants will receive standard medical care as directed by their doctor. For the research portion, participants will provide blood samples at specific times: at the time of diagnosis, shortly after surgery, right after finishing their first-line chemotherapy, and then every 3 months during regular follow-up visits. Researchers will also analyze a sample of the tumor tissue that was already removed during the patient's standard surgery.\n\nBy tracking these participants for up to 3 years, researchers hope to discover if the ctDNA test can accurately identify patients who have a high risk of their cancer returning, and if it can detect this earlier than traditional imaging scans or standard blood tests like CA-125.",[45,46,47],"Ovarian Neoplasms","Carcinoma, Ovarian Epithelial","Ovarian Cancer",[49,50,51,52],"ctDNA","Minimal Residual Disease","MRD","Liquid Biopsy","NOT_YET_RECRUITING","2026-06-22",{"date":56,"type":57},"2026-06-26","ACTUAL",{"date":59,"type":40},"2026-07-01",{"date":61,"type":40},"2028-12-31",{"name":5,"class":6}]